Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.


Options:
A: Arm Label: Placebo 2 mL auto-injector; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo 2 mL auto-injector | Arm Label: Placebo 1 mL prefilled syringe; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo 1 mL prefilled syringe | Arm Label: Secukinumab 2 mL auto-injector; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 2 mL auto-injector | Arm Label: Secukinumab 1 mL prefilled syringe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab 1 mL prefilled syringe | Intervention Type: DRUG; Name: Placebo 2 mL auto-injector; Assigned to Arm(s): Placebo 2 mL auto-injector | Intervention Type: DRUG; Name: Placebo 1 mL prefilled syringe; Assigned to Arm(s): Placebo 1 mL prefilled syringe | Intervention Type: DRUG; Name: Secukinumab 2 mL auto-injector; Assigned to Arm(s): Secukinumab 2 mL auto-injector | Intervention Type: DRUG; Name: Secukinumab 1 mL prefilled syringe; Assigned to Arm(s): Secukinumab 1 mL prefilled syringe
B: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1

Answer: B